6Y1Q | pdb_00006y1q

Cortistatin analog with improved immunoregulatory activity

• PDB DOI: https://doi.org/10.2210/pdb6Y1Q/pdb
• BMRB: 34491

• Classification: HORMONE
• Organism(s): synthetic construct
• Mutation(s): No 


• Deposited: 2020-02-13 Released: 2021-01-27 
• Deposition Author(s): Rol, A.
• Funding Organization(s): Ministry of Economy and Competitiveness (MINECO)

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 200 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Literature

Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease.

Rol, A., Todorovski, T., Martin-Malpartida, P., Escola, A., Gonzalez-Rey, E., Aragon, E., Verdaguer, X., Valles-Miret, M., Farrera-Sinfreu, J., Puig, E., Fernandez-Carneado, J., Ponsati, B., Delgado, M., Riera, A., Macias, M.J.

(2021) Nat Commun 12: 1869-1869

• PubMed: 33767180 
• DOI: https://doi.org/10.1038/s41467-021-22076-5
• Primary Citation Related Structures: 
  6Y1Q


• PubMed Abstract: 
  

  Ulcerative colitis and Crohn's disease are forms of inflammatory bowel disease whose incidence and prevalence are increasing worldwide. These diseases lead to chronic inflammation of the gastrointestinal tract as a result of an abnormal response of the immune system. Recent studies positioned Cortistatin, which shows low stability in plasma, as a candidate for IBD treatment. Here, using NMR structural information, we design five Cortistatin analogues adopting selected native Cortistatin conformations in solution. One of them, A5, preserves the anti-inflammatory and immunomodulatory activities of Cortistatin in vitro and in mouse models of the disease. Additionally, A5 displays an increased half-life in serum and a unique receptor binding profile, thereby overcoming the limitations of the native Cortistatin as a therapeutic agent. This study provides an efficient approach to the rational design of Cortistatin analogues and opens up new possibilities for the treatment of patients that fail to respond to other therapies.

---

Organizational Affiliation: 
• Institute for Research in Biomedicine (IRB-Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC), Armilla, Granada, Spain.
Departament de Química Inorgànica i Orgànica, Secció de Química Orgànica, Universitat de Barcelona, Barcelona, Spain.
BCN Peptides S.A. Pol.Ind. Els Vinyets-Els Fogars, Barcelona, Spain.
Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC), Armilla, Granada, Spain. [e-mail].
Institute for Research in Biomedicine (IRB-Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain. [e-mail].
Departament de Química Inorgànica i Orgànica, Secció de Química Orgànica, Universitat de Barcelona, Barcelona, Spain. [e-mail].
Institute for Research in Biomedicine (IRB-Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain. [e-mail].
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content 

• Total Structure Weight: 1.93 kDa 
• Atom Count: 134 
• Modeled Residue Count: 14 
• Deposited Residue Count: 14 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Analog 5	A	14	synthetic construct	Mutation(s): 0

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
OCA	B [auth A]	OCTANOIC ACID (CAPRYLIC ACID) C8 H16 O2 WWZKQHOCKIZLMA-UHFFFAOYSA-N

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
DTR	A	D-PEPTIDE LINKING	C11 H12 N2 O2		--
O6H	A	L-PEPTIDE LINKING	C12 H17 N O2		TRP

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 200 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Structure Validation

Entry History 

& Funding Information

Deposition Data

• Released Date: 2021-01-27 
Deposition Author(s): Rol, A.

---

Funding Organization	Location	Grant Number
Ministry of Economy and Competitiveness (MINECO)	Spain	RTI2018-100700-B-100

Revision History  

• Version 1.0: 2021-01-27
  Type: Initial release
  
• Version 1.1: 2021-04-07
  Changes: Database references
• Version 1.2: 2022-12-28
  Changes: Database references
• Version 2.0: 2023-11-15
  Changes: Atomic model, Data collection, Derived calculations
• Version 3.0: 2024-07-10
  Changes: Data collection, Database references, Derived calculations, Non-polymer description, Structure summary